

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Acting Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

June 9, 2016

Inter-Tribal Council of Nevada
Executive Board President
Vinton Hawley, Chairman
P.O. Box 256
Nixon, NV 89424

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

Revisions to Section 1203 of MSM Chapter 1200, Prescribed Drugs, include clarifying policy, defining a medically accepted indication, and clarifying the usage of the Standard Preferred Drug List Exception criteria. Under Immunizations, the Human Papillomavirus (HPV) Vaccine, the language for females only was removed. Under Coverage and Limitations, references to the Drug Utilization Review (DUR) Board and the Preferred Drug List (PDL) were removed. Family planning language was removed. Under Provider Responsibility, language was added regarding pharmacist submitted prior authorizations.

Revisions to Appendix A were made to reflect approved actions by the Drug Use Review (DUR) Board at the January 28, 2016, and April 28, 2016 meetings.

The DUR Board is a requirement of the Social Security Act to identify and reduce fraud, abuse, overuse, and medically unnecessary care. The DUR Board also works to minimize drug interactions, drug-induced illness, and undesirable drug reactions in recipients.

On January 28, 2016, revised prior authorization criteria was approved for Hepatitis C direct-acting antivirals, Proprotein Convertase Subtilism Kexin Type 9 (PCSK9) Inhibitors; Colchicine (Colcrys®); ADHD/ADD Agents; Hetlioz® (tasimelteon) and Vivitrol® (naltrexone). New prior authorization criteria were approved for hospice recipients over age 20.

June 9, 2016

Page 2

On April 28, 2016, revised prior authorization criteria was approved for generic substitutions; colony stimulating factors; narcotic withdrawal therapy agents; and long-acting narcotics. New prior authorization criteria were approved for Viberzi® (eluxadoline); Diclegis® (doxylamine/pyridoxine); Neurokinin-1 Antagonists and Combinations; pharmacist submitted prior authorizations, and opioid-induced constipation agents. The DUR Board also discussed gender dysphoria disorder and no action was needed.

There will be no fiscal impact for the tribes due to these changes.

If you would like a consultation regarding this new policy, please contact Tanya Benitez at (775) 684-3722 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,



Lynne Foster
Chief of Division Compliance

Cc: Elizabeth Aiello, Deputy Administrator
Shannon Sprout, Chief, Clinical Policy Team
Mary Griffith, Social Services Program Specialist, Clinical Policy Team